EQRx, Inc.
NASDAQ:EQRX
Overview | Financials
| Company Name | EQRx, Inc. |
| Symbol | EQRX |
| Currency | USD |
| Price | 2.34 |
| Market Cap | 1,140,551,119 |
| Dividend Yield | 0% |
| 52-week-range | 1.58 - 4.75 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Ms. Melanie I. Nallicheri |
| Website | https://www.eqrx.com |
An error occurred while fetching data.
About EQRx, Inc.
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD









